ACE and diabetes mellitus: In the DREAM (Diabetes Reduction Assessment with Ramipiril and Rosiglitazone Medication) trial, 5962 patients were randomized to ramipiril (an angiotensin-converting enzyme inhibitor), rosiglitazone, ramipiril and rosiglitazone, and a placebo.